The purpose of this project is to identify the critical regulators of remyelination in multiple sclerosis (MS) brains. It has been long established that oligodendrocyte progenitor cells (OPCs) populate MS lesions but do not transform into mature oligodendrocytes (OL) for reasons that remain unresolved. Therefore, one of the critical questions to ask is can we identify factors that prevent these cells from being able to mature and remyelinate? In recent years, microRNAs (miRNAs) have been identified as critical regulators of gene expression. We performed a comprehensive analysis of MS white matter lesions and identified 9 miRNAs that target 12 genes associated with the maturation of OPCs into mature OLs.
Aim 1 in the current proposal will therefore validate these miRNAs and target genes in MS brains, specifically in grey matter.
Aim 2 will build on these findings and provide in vitro evidence of the capacity of these miRNAs to induce myelination in OPCs. The next question to be answered is does loss of miRNAs lead to decreased remyelination by halting the progression of OPCs maturing into myelinating OLs in vivo? We propose to answer this question by using mice with loss of the miRNA processing enzyme Dicer in mature OLs and in OPCs. The role of miRNAs in promoting remyelination in vivo will be tested in Aim 3. The future of MS therapeutics lies in the identification of additional therapeutic targets and in developing combinatorial strategies. By characterizing failed myelin repair in MS brains, the studies outlined in this proposal should identify novel targets that will enhance repair of the MS brain.
Multiple Sclerosis (MS) is an inflammatory demyelinating and neurodegenerative disease of the central nervous system. While current anti-inflammatory therapies are effective during the initial relapsing phase of the disease, limited success is achieved during the progressive disease course. Promoting remyelination is considered to be the best option for the treatment of progressive MS. This project is designed to further enhance our understanding of the factors that influence remyelination in MS. Our data have identified several critical regulators that could account for failed myelin repair in MS brains. The current study will further investigate these regulators and could lead to the development of novel therapeutic approaches to repair the damage caused by demyelination and to improve the lives of patients with MS.
| Savarin, Carine; Dutta, Ranjan; Bergmann, Cornelia C (2018) Distinct Gene Profiles of Bone Marrow-Derived Macrophages and Microglia During Neurotropic Coronavirus-Induced Demyelination. Front Immunol 9:1325 |
| Dutta, Ranjan; Trapp, Bruce D (2018) Much, if not all, of the cortical damage in MS can be attributed to the microglial cell - No. Mult Scler 24:897-899 |
| Kremer, David; Akkermann, Rainer; Küry, Patrick et al. (2018) Current advancements in promoting remyelination in multiple sclerosis. Mult Scler :1352458518800827 |
| Bastian, Chinthasagar; Quinn, John; Tripathi, Ajai et al. (2018) CK2 inhibition confers functional protection to young and aging axons against ischemia by differentially regulating the CDK5 and AKT signaling pathways. Neurobiol Dis : |
| Chomyk, Anthony M; Volsko, Christina; Tripathi, Ajai et al. (2017) DNA methylation in demyelinated multiple sclerosis hippocampus. Sci Rep 7:8696 |
